Exploring apoptotic pathways in SH-SY5Y neuroblastoma cells: combined effects of napabucasin and doxorubicin

Basit Öğe Kaydı
dc.contributor.authorUnlu, Ilker
dc.contributor.authorTuncer, Mehmet Cudi
dc.contributor.authorOzdemir, Ilhan
dc.date.accessioned2026-01-31T15:09:10Z
dc.date.available2026-01-31T15:09:10Z
dc.date.issued2025
dc.departmentİstanbul Beykent Üniversitesi
dc.description.abstractBackground: Neuroblastoma often begins in infancy and is one of the most common types of cancer among children. Napabucasin (NP) (BBI608), a natural naphthoquinone emerging as a novel inhibitor of STAT3, has been found to effectively kill cancer stem-like tumour cells. However, the effect of napabucasin on SH-SY5Y cells is currently unclear. The aim of this study was to investigate the effects and mechanisms of NP and doxorubicin (DX) on human metastatic neuroblastoma cells. Materials and methods: In this study, human neuroblastoma cells line (SHSY--5Y) were used. Apoptotic activation of NP and DX via the Bcl-2/Bax signalling pathway was evaluated by qRT-PCR, Western blotting and Tali cytometry. It was also detected by MTT, a cell viability test. Results: NP and DX antiproliferatively and invasively affected SH-SY5Y cells. Additionally, NP induced apoptosis by pausing the cell cycle. Moreover, NP treatment inhibited the expression of Bcl-2, which is associated with apoptosis, while it clearly inhibited the expression of Bax and CASP3 genes. Conclusions: Our results show that NP and DX suppress the proliferation of neuroblastoma cells and could do this through apoptotic pathways. NP can be used to suppress metastasis of SHSY-5Y cells as an inhibitor of the apoptosis pathway Bcl-2. We suggest that NP, which provides tumour suppression through an apoptotic mechanism, may be an alternative treatment agent in neurological cancers such as neuroblastoma. (Folia Morphol 2025; 84, 3: 544-552)
dc.identifier.doi10.5603/fm.103887
dc.identifier.endpage552
dc.identifier.issn0015-5659
dc.identifier.issn1644-3284
dc.identifier.issue3
dc.identifier.pmid39822090
dc.identifier.scopus2-s2.0-105018890362
dc.identifier.scopusqualityQ2
dc.identifier.startpage544
dc.identifier.urihttps://doi.org./10.5603/fm.103887
dc.identifier.urihttps://hdl.handle.net/20.500.12662/10847
dc.identifier.volume84
dc.identifier.wosWOS:001598407600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherVia Medica
dc.relation.ispartofFolia Morphologica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260128
dc.subjectnapabucasin
dc.subjectapoptosis
dc.subjectSH-SY5Y
dc.subjectneuroblastoma
dc.subjectdoxorubicin
dc.titleExploring apoptotic pathways in SH-SY5Y neuroblastoma cells: combined effects of napabucasin and doxorubicin
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu